J&J Q3 Earnings: The US$100bn Revenue Goal Remains in Reach
Johnson & Johnson has not tried to hide its 2026 revenue goal. The US$100bn figure – the highest in its 140-year history – has been a target referenced in its earnings reports throughout the year.
On 13 October 2026, the pharmaceutical giant published its Q3 earnings report, beating earnings estimates and recording total quarterly sales of US$25.4bn.
In doing so, Johnson & Johnson has also raised its full-year guidance to US$101.2bn.
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” explains CEO Joaquin Duato.
“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade,” he continues.
A diversified portfolio
Central to Johnson & Johnson’s continued success in 2026 is, according to Chief Financial Officer Joseph Wolk, the company’s “diversified portfolio.”
J&J's portfolio now includes 29 products and platforms generating at least US$1bn in annual sales, spanning its Innovative Medicine and MedTech divisions.
- US$25.4bn – Total sales recorded by Johnson & Johnson in Q3 2026.
- US$101.2bn – Revised full-year 2026 revenue guidance, taking Johnson & Johnson above its US$100bn milestone target.
- 68% – Year-on-year sales growth recorded by immunology treatment Tremfya in Q3.
- US$50bn+ – Johnson & Johnson’s target for annual oncology revenue by 2030, as it aims to become the world’s leading oncology company.
- 29 – Products and platforms across Innovative Medicine and MedTech generating at least US$1bn in annual sales.
The latest addition is Caplyta, which reached US$1bn in year-to-date sales, supported by demand for its use as an adjunctive treatment for major depressive disorder.
With this model in place, Joseph is “confident in our ability to exceed US$100bn in revenue for the first time in our company’s 140-year history.”
“We are confident in our ability to exceed US$100bn in revenue for the first time in our company’s 140-year history. ”
Innovative Medicines and MedTech divisions
Johnson & Johnson’s Innovative Medicine division was central to its strong Q3 performance, generating US$16.8bn in sales.
Growth was led by immunology treatment Tremfya, which recorded a 68% increase in sales, alongside contributions from other medicines in the portfolio, including Darzalex and Tecvayli.
Oncology also delivered strong results, with sales increasing by 17% overall and Rybrevant sales rising by 64%. Johnson & Johnson aims to become the world’s leading oncology company by 2030, targeting annual revenue of more than US$50bn from the division.
Meanwhile, MedTech generated US$8.6bn in sales, driven by electrophysiology and shockwave technologies in Cardiovascular, contact lenses in Vision, and trauma products in Orthopaedics. However, the overall division fell short of the company’s expectations for the quarter.
As CEO Joaquin Duato acknowledged during the earnings call, “while we fell short of our expectations for the segment, our conviction in our future direction has not changed.”
Joseph similarly highlighted the importance of Innovative Medicine in delivering the quarterly results, saying: “Our third-quarter results were driven by the strength of our Innovative Medicine business.
“This performance more than offset headwinds in certain areas of MedTech, enabling us to exceed expectations on both the top and bottom line, while continuing to invest in our pipeline and future growth.”
Future direction
Looking beyond its immediate financial performance, Johnson & Johnson is positioning its portfolio and pipeline to sustain growth through the end of the decade.
In Innovative Medicine, this includes strengthening its oncology capabilities through acquisitions and new clinical developments. Johnson & Johnson completed its US$1bn acquisition of Firefly Bio during the quarter, adding antibody-engineering capabilities to support the development of cancer treatments.
MedTech's future growth will depend on bringing new technologies to market and improving performance in areas that fell short of expectations in Q3. Its Ottava surgical robotic system received US FDA De Novo authorisation in July 2026, while its Varipulse Pro cardiovascular platform received approval in Japan during the quarter.
Johnson & Johnson - key partners
Genmab
CEO: Jan van de Winkel | HQ: Copenhagen, Denmark
Genmab is a biotechnology company specialising in the development of antibody-based medicines for cancer and other serious diseases. Its collaboration with Johnson & Johnson has produced Darzalex, a key treatment for multiple myeloma, alongside wider work on bispecific antibody technologies. The partnership supports Johnson & Johnson’s oncology portfolio and its ambition to become the world’s leading oncology company by 2030.
Legend Biotech
CEO: Ying Huang | HQ: Somerset, New Jersey
Legend Biotech is a global biotechnology company focused on developing and commercialising cell therapies for cancer. It partners with Johnson & Johnson to develop and commercialise CAR-T treatment Carvykti for patients with multiple myeloma. The collaboration combines Legend Biotech’s cell therapy expertise with Johnson & Johnson’s clinical development and commercial capabilities, strengthening its position in advanced oncology treatments.
Company portals
Executives
Joaquin Duato
Chairman of the Board and Chief Executive Officer
Joseph Wolk
Executive Vice President, Chief Financial Officer
